Recent Reports


2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 38 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
VINIT SAXENA - SEPRAGEN CORPORATION (SPGNA)


Full article published: 05/10/1999


For Subscribers

Get this article online now!

Order just this article
TWST: Can you give us a brief overview and a little bit of the history of the company, just to kind of set the scene for the readers?
Mr. Saxena: The company is a high technology separations company. We develop and market technology and equipment that are designed to enable our customers to separate various things from complex liquid mixtures. We have a variety of markets that we service. The first one is the biotechnology industry, wherein our products are used by biotechnology companies to isolate, to purify various biological drugs that are intended to be used in patients for therapeutic purposes. I believe eight or nine FDA approved drugs are currently using our products in the manufacturing process. Secondly, our technology is also in the dairy industry to isolate proteins from dairy whey, and thirdly our technology has exciting applications in the juice industry. As you can see, there are a number of vertical applications for our technology only a few of which have currently been developed. The company has been a development stage company and we're now transitioning into commercialization.

TWST: Who are the prime customers for your products?
Mr. Saxena: In the biotechnology industry, our customers include Baxter, Schering-Plough, Human Genome Sciences, Chiron Corporation, Glaxo-Wellcome; and a wide variety of first-tier customers. In the dairy industry, we've recently announced deals with two leading dairy ingredient suppliers of international standing. One is Anchor Products of New Zealand. Anchor, through the New Zealand Dairy Board, accounts for over 30 percent of the world export business in high end diary food ingredients, and they are a several billion dollar company. Pursuant to our agreement, Anchor will use our technology to produce certain dairy proteins, which will be extracted from whey, and will be targeted for high end uses such as differentiated infant formula, which is closer to human milk, as nutracentical supplements.

 

Tickers included in this excerpt: SPGNA

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.